283 related articles for article (PubMed ID: 35506332)
41. Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib.
Yamamiya I; Hunt A; Takenaka T; Sonnichsen D; Mina M; He Y; Benhadji KA; Gao L
Clin Pharmacol Drug Dev; 2023 Oct; 12(10):966-978. PubMed ID: 37132707
[TBL] [Abstract][Full Text] [Related]
42. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
Li A; Yeo K; Welty D; Rong H
Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
[TBL] [Abstract][Full Text] [Related]
43. Physiologically based pharmacokinetic modeling of ponatinib to describe drug-drug interactions in patients with cancer.
Morita TO; Hanada K
Cancer Chemother Pharmacol; 2022 Oct; 90(4):315-323. PubMed ID: 35997844
[TBL] [Abstract][Full Text] [Related]
44. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
45. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Otsuka Y; Poondru S; Bonate PL; Rose RH; Jamei M; Ushigome F; Minematsu T
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):365-376. PubMed ID: 37344637
[TBL] [Abstract][Full Text] [Related]
46. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Chiney MS; Ng J; Gibbs JP; Shebley M
Clin Pharmacokinet; 2020 May; 59(5):617-627. PubMed ID: 31713224
[TBL] [Abstract][Full Text] [Related]
47. Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.
Bowman C; Dolton M; Ma F; Cheeti S; Kuruvilla D; Sane R; Kassir N; Chen Y
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):660-672. PubMed ID: 38481038
[TBL] [Abstract][Full Text] [Related]
48. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
49. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A
Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518
[TBL] [Abstract][Full Text] [Related]
50. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
51. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
52. A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4.
Liu T; Gobburu JVS
J Pharm Sci; 2018 Mar; 107(3):942-948. PubMed ID: 29102550
[TBL] [Abstract][Full Text] [Related]
53. In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G; Fowler S; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Mercier F; Ullah M; Umehara K; Brink A; Buchheit V; Zwanziger E; Phipps A; Djebli N
Invest New Drugs; 2022 Feb; 40(1):68-80. PubMed ID: 34417912
[TBL] [Abstract][Full Text] [Related]
54. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
[TBL] [Abstract][Full Text] [Related]
55. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
56. Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Cicali B; Lingineni K; Cristofoletti R; Wendl T; Hoechel J; Wiesinger H; Chaturvedula A; Vozmediano V; Schmidt S
CPT Pharmacometrics Syst Pharmacol; 2021 Jan; 10(1):48-58. PubMed ID: 33217171
[TBL] [Abstract][Full Text] [Related]
57. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
58. Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin.
Yee KL; Cabalu TD; Kuo Y; Fillgrove KL; Liu Y; Triantafyllou I; McClain S; Dreyer D; Wenning L; Stoch SA; Iwamoto M; Sanchez RI; Khalilieh SG
J Clin Pharmacol; 2021 Mar; 61(3):394-405. PubMed ID: 32989795
[TBL] [Abstract][Full Text] [Related]
59. Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.
Chen J; Stringer R; Shah B; Gu J; Zhang Y; Hackling M; Prince W; Woessner R
Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1253-1263. PubMed ID: 35962468
[TBL] [Abstract][Full Text] [Related]
60. Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.
Pilla Reddy V; Walker M; Sharma P; Ballard P; Vishwanathan K
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):321-330. PubMed ID: 29468841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
